Zydus Lifesciences’ wholly owned subsidiary, Zydus Lifesciences Global FZE has inked an exclusive licensing, supply and commercialization agreement with Zhuhai Beihai Biotech Co. for BEIZRAY (Albumin Solubilized Docetaxel Injection), a 505(B)(2) product for the US market.
The partnership will provide impetus to company’s strategic focus on high unmet need therapy area. BEIZRAY is indicated for the treatment of Breast Cancer, Non-small Cell Lung Cancer, Prostate Cancer, Gastric Adenocarcinoma, and Head and Neck Cancer. Under the agreement, Beihai Biotech will be responsible for the manufacturing and supply of the product, while Zydus will be responsible for commercialization of the product in the US. Beihai Biotech shall receive upfront payments, sales targets-based milestone payments and a share of BEIZRAY’s net profits earned in the US as per the terms of the agreement.
Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
